{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:13:48Z","timestamp":1790835228218,"version":"4.1.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2022,8,23]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Clinical worsening (CW) is a composite end point commonly used in pulmonary arterial hypertension (PAH) trials. We aimed to assess the trial-level surrogacy of CW for mortality in PAH trials, and whether the various CW components were similar in terms of frequency of occurrence, treatment-related relative risk (RR) reduction, and importance to patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched MEDLINE, Embase, and the Cochrane Library (January 1990 to December 2020) for trials evaluating the effects of PAH therapies on CW. The coefficient of determination between the RR for CW and mortality was assessed by regression analysis. The frequency of occurrence, RR reduction, and importance to patients of the CW components were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              We included 35 independent cohorts (9450 patients). PAH therapies significantly reduced CW events (RR, 0.64 [95% CI, 0.55\u20130.73]), including PAH-related hospitalizations (RR, 0.61 [95% CI, 0.47\u20130.79]), treatment escalation (RR, 0.57 [95% CI, 0.38\u20130.84]) and symptomatic progression (RR, 0.58 [95% CI, 0.48\u20130.69]), and modestly reduced all-cause mortality when incorporating deaths occurring after a primary CW-defining event (RR, 0.860 [95% CI, 0.742\u20130.997]). However, the effects of PAH-specific therapies on CW only modestly correlated with their effects on mortality (\n              <jats:italic>R<\/jats:italic>\n              <jats:sup>2<\/jats:sup>\n              <jats:sub>trial<\/jats:sub>\n              , 0.35 [95% CI, 0.10\u20130.59];\n              <jats:italic>P<\/jats:italic>\n              &lt;0.0001), and the gradient in the treatment effect across component end points was large in the majority of trials. The weighted proportions of CW-defining events were hospitalization (33.5%) and symptomatic progression (32.3%), whereas death (6.7%), treatment escalation (5.6%), and transplantation\/atrioseptostomy (0.2%) were infrequent. CW events were driven by the occurrence of events of major (49%) and mild-to-moderate (37%) importance to patients, with 14% of the events valued as critical.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PAH therapies significantly reduced CW events, but study-level CW is not a surrogate for mortality in PAH trials. Moreover, components of CW largely vary in frequency, response to therapy, and importance to patients and are thus not interchangeable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration:<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/PROSPERO\">https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n              ; Unique identifier: CRD42020178949.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.121.058635","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T18:00:17Z","timestamp":1661191217000},"page":"597-612","source":"Crossref","is-referenced-by-count":25,"title":["Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1161","volume":"146","author":[{"given":"\u00c9lodie","family":"Tremblay","sequence":"first","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Gosselin","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-7109","authenticated-orcid":true,"given":"Vicky","family":"Mai","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie C.","family":"Lajoie","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubi","family":"Kilo","sequence":"additional","affiliation":[{"name":"P\u00f4le De Sant\u00e9 Publique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69310, Pierre-B\u00e9nite, France (R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Weatherald","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Respiratory Medicine, Libin Cardiovascular Institute, University of Calgary, Canada (J.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lacasse","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Department of Medicine (Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-1900","authenticated-orcid":true,"given":"Sebastien","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Department of Medicine (Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, UMR 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Centre national de la recherche scientifique, F-69100, Groupe d\u2019Etude Multidisciplinaire des Maladies Thrombotiques, Department of Internal and Vascular Medicine, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69310, Lyon, France (J.-C.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-9972","authenticated-orcid":true,"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec Research Center (E.T., C.G., V.M., A.C.L., Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Department of Medicine (Y.L., S.B., S.P.), Universit\u00e9 Laval, Quebec City, Canada."},{"name":"Pulmonary Hypertension Research Group Quebec City, Canada (E.T., C.G., V.M., A.C.L., S.B., S.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.84"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.105890"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.01.083"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-3023"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.007"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7491.594"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.10.020"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39136.682083.AE"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2554"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.06.065"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.034"},{"key":"e_1_3_3_13_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3 (updated February 2022)","author":"Higgins J","year":"2022","unstructured":"Higgins, J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, M, Welch, Ve. Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3 (updated February 2022). Cochrane, 2022. https:\/\/www.training.cochrane.org\/handbook."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4065\/75.12.1284"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104"},{"key":"e_1_3_3_20_2","volume-title":"2005-. Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1","year":"2011","unstructured":"Institute for Quality and Efficiency in Health Care: Executive Summaries. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-. Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1. Nov 21, 2011."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/1.1.49"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201400049"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13740"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00057906"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2875"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.124388"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1640OC"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.05.006"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0093OC"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-017-0674-3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.28"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02044-2014"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.10.002"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30532-4"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02493-2016"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1375"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01030-2019"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30307-1"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1180-1"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"e_1_3_3_60_2","unstructured":"A Phase 3 Multi-Center Randomized Double-Blind Efficacy and Safety Study of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium and Sildenafil Citrate in Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001. Accessed January 30 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00796666"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.057"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f457"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa665"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01919-2018"},{"key":"e_1_3_3_65_2","unstructured":"US Food and Drug Administration. The Voice of the Patient: Pulmonary Arterial Hypertension. 2014. Accessed June 30 2021. www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM429382.pdf"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.010"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.08.020"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.43"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.81"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.121.058635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:26:56Z","timestamp":1661434016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.121.058635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,23]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.121.058635"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.121.058635","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]}}}